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Abstract
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their infectious capabilities. As science advances, many of the mechanisms for microbial survival and
resistance element transfer have been identified. During the 2012 meeting of Antimicrobial Agents in
Veterinary Medicine (AAVM), experts provided insights on such issues as use vs. resistance, the available
tools for supporting appropriate drug use, the importance of meeting the therapeutic needs within the
domestic animal health care, and the requirements associated with food safety and food security. This report
aims to provide a summary of the presentations and discussions occurring during the 2012 AAVM with the
goal of stimulating future discussions and enhancing the opportunity to establish creative and sustainable
solutions that will guarantee the availability of an effective therapeutic arsenal for veterinary species.
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Antimicrobial resistance is a global challenge that impacts both human and
veterinary health care. The resilience of microbes is reflected in their ability
to adapt and survive in spite of our best efforts to constrain their infectious
capabilities. As science advances, many of the mechanisms for microbial sur-
vival and resistance element transfer have been identified. During the 2012
meeting of Antimicrobial Agents in Veterinary Medicine (AAVM), experts
provided insights on such issues as use vs. resistance, the available tools for
supporting appropriate drug use, the importance of meeting the therapeutic
needs within the domestic animal health care, and the requirements associ-
ated with food safety and food security. This report aims to provide a sum-
mary of the presentations and discussions occurring during the 2012 AAVM
with the goal of stimulating future discussions and enhancing the opportu-
nity to establish creative and sustainable solutions that will guarantee the
availability of an effective therapeutic arsenal for veterinary species.
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Marilyn Martinez, US Food and Drug Administration, Center for Veterinary
Medicine, Office of New Animal Drug Evaluation (HFV-100), Rockville, MD
20855, USA. E-mail: Marilyn.Martinez@fda.hhs.gov
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INTRODUCTION
The threat of infectious diseases is a concern impacting both
human and animal health. The emergence of antimicrobial
resistance threatens the effectiveness of our existing therapeutic
arsenal. Therefore, the development and spread of pathogenic
and nonpathogenic organisms that carry resistance genes are
a cause of increasing concern (Anon 1, Anon 8). However,
this is not a new phenomenon, and there is evidence that anti-
microbial resistance is an ancient mechanism in the life cycle
of bacteria (D’Costa et al., 2011; Bhullar et al., 2012).
As stated by Vaarten at the 2012 meeting of the World
Organization for Animal Health (OIE), antimicrobial use in ani-
mals is an essential part of our efforts to control those bacterial
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infections responsible for causing pain and suffering, tissue
damage, organ dysfunction, weight loss, and loss of productiv-
ity. The benefits associated with judicious drug use include pro-
tecting animal health and welfare as well as supporting the
availability of foods of animal origin. It also reduces the risk of
spreading (zoonotic) infections, allows for the containment
of potentially large-scale epidemics, and supports the protection
of people’s livelihoods and animal resources (Simmons, 2011).
The 2012 meeting of Antimicrobial Agents in Veterinary
Medicine (AAVM) was convened to promote a dialog on crea-
tive and sustainable solutions to the global threat of antimicro-
bial resistance. Emphasizing the role of ‘SCIENCE’ as the
mechanism for enhancing our understanding of the problem at
hand, the theme of a 3-D approach was selected because of the
inextricable interactions between humans, the treated animals,
the environment, and wildlife. Through the platform of invited
lectures and subsequent discussions, the 2012 AAVM provided
an opportunity for research scientists, regulatory scientists, vet-
erinary practitioners, and drug sponsors to explore practical
solutions for important public health challenges.
WORKSHOP SUMMARY
Part 1: Regulatory approach to address veterinary antimicrobial use
concerns
Critically important drugs for human health: a WHO/FAO/OIE
perspective. The first Joint Food and Agriculture Organization
(FAO)/OIE/World Health Organization (WHO) Expert Workshop
on Non-Human Antimicrobial Usage and Antimicrobial
Resistance: Scientific assessment took place in Geneva in 2003
http://www.who.int/foodsafety/publications/micro/en/amr.pdf.
A Second Joint FAO/OIE/WHO Expert Workshop on Non-
Human Antimicrobial Usage and Antimicrobial Resistance:
Management options was held in 2004 in Oslo, Norway http://
www.oie.int/fileadmin/Home/eng/Conferences_Events/docs/pdf/
WHO-CDS-CPE-ZFK-2004.8.pdf.
Thereafter, the WHO convened an Expert Meeting on Criti-
cally Important Antimicrobials for Human Medicine, in Copen-
hagen, Denmark, in May 2007 (Anon 7) and a Joint FAO/
WHO/OIE Expert Meeting on Critically Important Antimicrobi-
als in November 2007 (Anon 8). The joint FAO/WHO/OIE
report provided a list of critically important antimicrobials in
humans and in terrestrial food-producing animals. This list
was further modified in 2011 by the WHO Advisory Group on
Integrated Surveillance of Antimicrobial Resistance (AGISAR).
This revised list included not only newly developed drugs and
scientific information but also a list of the specific compounds
within each of these classes according to their use within
either human or veterinary medicine (Anon 7). The resulting
AGISAR ranking of drug classes in accordance to their impor-
tance to human medicine is provided in Table 1.
Much overlap is seen between compounds of importance to
human and to animal health. Therefore, it was recommended
that those drug classes listed as the highest for risk manage-
ment strategies should include the (fluoro)quinolones, 3rd and
4th generation cephalosporins, and the macrolides. Resistance
against these drug groups is detected in foodborne pathogens,
namely Salmonella spp. and Campylobacter spp., and the com-
mensal Escherichia coli.
It is important to emphasize that while these discussions
focused solely on antimicrobial use in food-producing animals,
it was concluded that antimicrobial use in nonfood-producing
animals should also be subject to the prudent use provisions of
the OIE Terrestrial Animal Health Code, 2012 (Anon 2).
United States Food and Drug Administration approach for
addressing veterinary antimicrobial use concerns. To address
Table 1. Categorization of antimicrobials used in human medicine according to their importance in treatment of disease
Critically important antimicrobials Highly important antimicrobials Important antimicrobials
Aminoglycosides* Amdinopenicillins Aminocyclitols
Carbapenems and other penems Amphenicols* Cyclic polypeptides
Cephalosporins (3rd and 4th generations)* Cephalosporins (1st and 2nd generations)
and cephamycins*
Nitrofurantoins*
Cyclic esters Lincosamides* Nitroimidazoles
Fluoro and other quinolones* Penicillins (Antistaphylococcal)*
Glycopeptides* Pleuromutilins*
Glycylcyclines Pseudomonic acids
Lipopeptides Riminofenazines
Macrolides and ketolides* Steroid antibacterials
Monobactams Streptogramins*
Oxazolidinones Sulfonamides, dihydrofolate reductase
inhibitors, and combinations*
Penicillins (natural, aminopenicillins, and
antipseudomonal)*
Sulfones
Polymyxins Tetracyclines*
Rifamycins
Drugs used solely to treat tuberculosis or other
mycobacterial diseases
*Member(s) in the classes may have veterinary uses. They are examples and variations may exist among various regions or countries.
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public health concerns associated with the use of
antimicrobials in food-producing animals, the United States
Food and Drug Administration (US FDA) Center for Veterinary
Medicine (CVM) published three regulatory documents: (i)
Guidance for Industry (GFI) #209 (Judicious use of Medically
Important Antimicrobial Drugs in Food-Producing Animals;
Anon 4); (ii) draft GFI 213 (New Animal Drugs and New
Animal Drug Combination Products Administered in or on
Medicated Feed or Drinking Water of Food Producing Animals:
Recommendations for Drug Sponsors for Voluntarily Aligning
Product Use Conditions with GFI #209; Anon 5); and (iii) the
Veterinary Feed Directive (VFD; Anon 3).
a) GFI #209: This guidance is built on the principle that ‘use
of medically important antimicrobial drugs in food-produc-
ing animals should be limited to those uses that are consid-
ered necessary for assuring animal health’. Furthermore,
the administration of medically important antimicrobial
drugs in food-producing animals should be limited to uses
that include veterinary oversight or consultation.
b) Draft GFI #213: This document describes implementation of
the key principles in GFI #209 based upon concepts set out
in GFI #152, ‘Evaluating the Safety of Antimicrobial New
Animal Drugs with Regard to their Microbiological Effects
on Bacteria of Human Health Concern’, which includes an
appendix that ranks antimicrobial drugs as ‘critically impor-
tant’, ‘highly important’, or ‘important’, in regard to their
relevance to human medicine. This draft GFI provides a pro-
cess for updating product labels and describes the data
requirements for adding new indications. In this regard,
new prevention uses are expected to include a defined dose
duration, an effective therapeutic dose level, the disease at-
risk population, and mechanisms for veterinary oversight
(i.e., changing marketing status from over the counter
[OTC] to either prescription or the VFD.
c) The VFD: This provides a mechanism for requiring produc-
ers to secure approval from a veterinarian prior to the
administration of medicated articles.
The VFD is the primary mechanism for veterinary oversight
of antimicrobials administered in animal feed. It is prescription-
like, but is intended solely for feed. It serves as an alternative
to prescription status for certain therapeutic animal pharma-
ceuticals for use in feed. In essence, a VFD is a mechanism
requiring a producer to get approval from a veterinarian for
antibiotics used in feed. The Federal Food Drug and Cosmetic
Act (FFD&C) requires that medicated feeds needing veterinary
oversight be designated as VFDs. Regulations on the use of
VFDs were finalized in January 2001. The FDA intends to
move all medically important antibiotics out of OTC status
to VFD status. Expressed concerns with the VDF include as
follows:
a) The potential for prescription status requirements would lead
to major disruptions of existing marketplace practices for
drug sponsors, feed manufacturers, and animal producers.
b) State pharmacy laws and regulations intended to apply only
to the dispensing of other dosage forms of drugs, not to
medicated animal feed.
c) Statutory limitations on labeling and marketing practices
that would place covered drugs and feeds at a commercial
disadvantage when compared with OTC-medicated feeds.
Currently, there are only 2 VFD drugs, tilmicosin and florfe-
nicol.
There are several ongoing programs that facilitate efforts to
address the challenge of antimicrobial resistance. These include
the US Department of Agriculture (USDA), Antimicrobial Resis-
tance Work Plan involving the Food Safety Inspection Service,
Agricultural Research Service and Animal and Plant Health
Inspection Service, and the National Antimicrobial Monitoring
System (NARMS), which was jointed established by the FDA,
USDA, and the US Centers for Disease Control and Prevention
for the purpose of monitoring resistance among foodborne
pathogens from humans, retail meats, and animals http://
www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialRe
sistance/NationalAntimicrobialResistanceMonitoringSystem/
default.htm.
In the 112th US Congress, the leading bill on antimicrobial
resistance was the Preservation of Antibiotics for Medical Treat-
ment Act of 2011. As described by the Congressional Research
Service, which is a nonpartisan division of the Library of Con-
gress, this Act was intended to amend the FFD&C Act to
require the Secretary of Health and Human Services to deny
an application for a new animal drug that is a critical antimi-
crobial animal drug unless the applicant demonstrates that
there is a reasonably certainty of no harm to human health
due to the development of antimicrobial resistance attributable
to the nontherapeutic use of the drug. This amendment defines
‘critical antimicrobial animal drug’ as a drug intended for use
in food-producing animals that contains specified antibiotics or
other drugs used in humans to treat or prevent disease or
infection caused by micro-organisms. The bill was intended to
require the Secretary to withdraw approval of a nontherapeutic
use of such drugs in food-producing animals 2 years after the
date of enactment of this Act unless certain safety require-
ments are met. This bill was introduced on March 9, 2011, in
a previous session of Congress, but was not enacted. (http://
www.govtrack.us/congress/bills/112/hr965).
The European Union approach to stimulate the prudent use of
antimicrobials in animals. Several landmark regulatory actions
have had a significant influence on the use of antimicrobial
agents on European farms. These include (Cogliani et al.,
2011):
a) 1969: SWANN Report: Agricultural use of antibiotics (http://
hansard.millbanksystems.com/commons/1969/nov/20/
use-of-antibiotics-in-animal-husbandry). This report requires
the ban of certain antibiotics (e.g., penicillin and tetracyclins
for nonmedical (growth-promoting purposes) and recom-
mends placing all antibiotics under veterinary prescription.
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b) 1986: Sweden bans the use of antimicrobials for growth-
promotion in agriculture, as requested by Federation of
Swedish Farmers.
c) 1997: the European Union bans the use of avoparcin as a
growth promoter due to its potential cross-resistance with
vancomycin.
d) 1999: The Steering Committee of the European Commission
recommends phasing out the use of medically important
antimicrobials as growth promoters and implements disease
prevention methods. The ban included olaquindox and car-
badox. Authorization was suspended on bacitracin, tylosin,
spiramycin, and virginiamycin. http://ec.europa.eu/food/fs/
sc/ssc/out50_en.pdf
e) 2006: The European Commission issued a total ban of all
antimicrobial growth promoters, including flavomycin/bam-
bermycin and Zn-bacitracin.
Since 2006, all veterinary use of antimicrobials requires a
prescription (POM status, prescription-only medicines), and
that all licensed veterinary products are prescription-only
drugs. In addition, screening for methicillin-resistant Staphylo-
coccus aureus (MRSA) and extended spectrum b-lactamase
(ESBL)-producing E. coli in animal populations was initiated.
Along with these actions, hospital-acquired MRSA in compan-
ion animals was revisited, and a memorandum was issued
against the use of the 3rd and 4th generation cephalosporins.
The registration of antimicrobial use on farms was initiated.
Some countries, such as Denmark and the Netherlands, have
established action levels for the frequency of treatments
(expressed as daily doses per animal per year).
While various applications for antibiotics in farm animal
practice are restricted and controlled, research activities to
improve the range of vaccination programs are encouraged
and supported. This applies also to the use of feed additives
that improve animal sustainability, including several classes of
prebiotics and probiotics, organic acids, polysaturated fatty
acids, enzymes, and other feed (nonantibiotic) ingredients.
These nonantimicrobial compounds may help to stimulate the
animal’s immune system, reduce the risk for outbreak of
infections, and increase feed utilization. Legal requirements
have been set for the licensing of such compounds (EC 1831/
2003), demanding quality assurance procedures, and a dem-
onstration of activity and safety which is comparable to estab-
lished drug-licensing procedures. The overall objective is
disease prevention as a measure to reduce the need for thera-
peutic intervention.
Part 2: Methodology and interpretation of antimicrobial testing
Interpreting results from antimicrobial susceptibility
tests. Bacterial drug susceptibility is generally expressed
relative to the minimum drug concentration that inhibits
growth under a given set of in vitro test conditions (the
minimum inhibitory concentration [MIC]). A prerequisite for
any MIC determination is that it is generated through the use
of quality-controlled methods.
MICs are estimated on the basis of serial dilutions. Drug
potency is measured by the lowest concentration of an antimi-
crobial that inhibits bacterial growth after overnight exposure
when the test tube contains an inoculum size of 105 colony-
forming units (CFU) per mL of medium. The MIC serves as a
benchmark against which changes in susceptibility can be
tracked. It is also used to gauge dosages needed to treat infec-
tions based upon the application of PK and PD principles.
Despite reliance on these values, there are numerous poten-
tial shortcomings that need to be considered:
a) MIC: The MIC reflects a single component of the interaction
between a drug and a pathogen. The MIC value neither
reflects the impact of very low (subinhibitory) concentra-
tions on bacterial virulence nor can it distinguish between
static or cidal effects on a pathogen. The mode of action for
subinhibitory effects may not be the same as that associated
with the MIC (e.g., Garch et al., 2010). While nutrients or
their precursors necessary for bacterial survival may be
readily available in culture media, if absent in vivo, it can
reduce pathogen viability and virulence. In this way, there
can be differences in the in vitro vs. in vivo growth rates. In
turn, this can lead to difference in the in vivo vs. in vitro
concentrations needed to minimize bacterial growth.
b) Inoculum effects: Although in vitro tests are conducted at
an inoculum size of 105 CFU/mL, the microbial population
in infected tissues may be as high as 1010–1012 (Frisch
et al., 1942). For many compounds, the MIC increases as
inoculum increases. Examples of drugs associated with an
in vitro inoculum effect for S. aureus include ciprofloxacin,
oxacillin, daptomycin, and vancomycin (the latter two
potentially being associated with drug degradation), genta-
micin and linezolid (whose decrease in drug efficacy with
increasing inoculum may simply be attributable to a
decrease in per-cell antibiotic concentration; Udekwu et al.,
2009). Conversely, upon examining the potential inoculum
effect when E. coli is exposed to antibiotics that target the
ribosome, Tan et al. (2012) observed that while aminogly-
cosides (e.g., streptomycin, puromycin, gentamicin, tobra-
mycin, neomycin, and kanamycin) exhibit a decrease in
activity, other antibiotics such as chloramphenicol or the
tetracyclines are not associated with inoculum effects.
c) Sub-MIC effects: The mode of action for subinhibitory effects
may not be the same mode of action as that associated with
the MIC (e.g., Garch et al., 2010). See section 2.2.2 for
further discussion.
Establishment of appropriate dosage regimes: PK/PD
considerations. General principles. Within the framework of
veterinary medicine, the therapeutic goals include treatment
(when the patient has an active infection), control/
metaphylaxis (e.g., when there is evidence of an outbreak),
and prevention/prophylaxis (when there is a risk of a disease
outbreak but no evidence of infection within the herd, farm, or
house). Because of differences in the bacterial load (bioburden)
and in the patient’s physiological status, the concentrations
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needed to achieve the desired therapeutic outcome can differ as
a function of indication. This aspect if often incompletely
addressed in the authorized dosage regimes. However, when
administering antimicrobials to food-producing animals, any
alteration of the dosage regime has also to consider the
potential impact of such a dosage regimes on withdrawal
periods and (microbial) human food safety.
Appropriate dosage regimes are a function of the exposure–
response relationship associated with the action of the antimi-
crobial agent and the targeted therapeutic outcome (e.g., static
effects, cidal effects, 1-log kill, and 3-log kill). Concentrations
are assessed relative to free (unbound) plasma or serum drug
concentrations because these are the concentrations most clo-
sely correlated with active drug concentrations at the site of
action. Antimicrobial exposure–response (PK/PD) relationships
are generally classified as being either time or concentration-
dependent (Craig, 2007), with all drugs exhibiting components
of both variables (Martinez et al., 2012). PK/PD relationships
are further expressed as time above MIC (T > MIC), peak
divided by the MIC (Cmax/MIC), or the extent of exposure (e.g.,
over a 24-h dosing interval) above the MIC (AUC/MIC). Exam-
ples of drugs falling within these classifications are as follow:
a) T > MIC: penicillins, cephalosporins, monobactams, and
carbapenems;
b) Cmax/MIC: aminoglycosides, fluoroquinolones, glycopeptides,
and daptomycin;
c) AUC/MIC: aminoglycosides, fluoroquinolones, glycopeptides,
daptomycin, oxazolidinones, and tetracyclines. Although
generally associated with time-dependent effects, the PK/PD
parameter correlated with clinical outcome for most of the
newer macrolides is also AUC/MIC due to its prolonged
postantibiotic effect.
Examples of the numerical values of these indices that have
been correlated with therapeutic success in human patients
were summarized by Ambrose et al. (2007). The many vari-
ables contributing to a therapeutic response include (Martinez
et al., 2013):
a) The susceptibility of the pathogen to the antimicrobial (i.e.,
the MIC of the antimicrobial agent).
b) The characteristics of the pathogen response to the antimi-
crobial (e.g., cidal vs. static effects, and kill rate).
c) The characteristics of the host–pathogen interaction and the
ability of the drug to influence this interaction such as:
i) the ability of the pathogen to invade or colonize on host
tissues;
ii) the secretion/release of toxins by the pathogen;
iii) the ability of subinhibitory concentrations to affect the
pathogen and pathogen–host interactions; and the accu-
mulation of certain antimicrobials in leukocytes.
d) The PK of the drug and the dosage form.
e) The dosage regime.
f) The effect of the antimicrobial on the host disease response
(e.g., drug anti-inflammatory effects).
g) The host’s immune status.
h) The magnitude of the bacterial burden (bioburden) at the
site of the infection.
i) The propensity of the pathogen to form resistant genotypes
and phenotypes (e.g., bacteria in biofilms).
Bioburden will likely differ when a drug is used for metaphy-
laxis, prophylaxis, or treatment. To ascertain whether or not
bioburden can influence clinical and bacteriological outcomes,
Ferran et al. (2011) used a non-neutropenic mouse-lung model
of Pasturella multocida infection (Ferran et al., 2011). In this
study, clinical and bacteriological outcomes for infected mice
were shown to be better, and the selection of resistance less
frequent, when marbofloxacin was administered as an early
intervention (10 h after inoculum administration) as compared
to treatment at 32 h after inoculum administration. Moreover,
the early dose of 1 mg/kg led to better clinical and similar bac-
teriological (eradication and selection of resistance) outcomes
as compared to the later dose of 40 mg/kg marbofloxacin
(curative therapy). These results support arguments favoring
the utility of drug metaphylaxis from a clinical perspective,
allowing for a reduction in both the total amount of drug
administered per animal and the risk of selecting for pathogen
resistance. Similar results have been obtained with amoxicillin
and cefquinome in the same model.
Estimating the dose. When dealing with drugs associated with
concentration-dependent killing, we need to consider the
relationship between the drug concentration, the MIC, and the
likelihood of selecting for drug resistance. The range of
concentrations where the risk is highest is known as the mutant
selection window (MSW; Blondeau et al., 2001, 2004; Drlica,
2003; Hansen et al., 2003; Hesje et al., 2007). The MSW defines
a ‘danger zone’ for therapeutic drug concentrations. This region
is flanked by the MIC and the mutant prevention concentration
(MPC), the latter reflecting concentrations at which the
likelihood for the selection of resistant strains is minimized.
However, the MSW concept is not straightforward and that
what matters is not simply the duration over which drug
concentrations are within the MSW but rather the proximity of
these concentrations to the MPC (Ferran et al., 2007).
The relationship between MIC and MPC for several patho-
gens and drugs were provided by Blondeau (2009). For com-
pounds where susceptibility can be altered by mutational
events, higher bioburdens increase the risk of selecting for
resistant bacterial strains. Accordingly, it has recently been
proposed that the MPC be based on the testing of larger bacte-
rial inocula, that is, ≥109 CFU/mL, as such a high population
includes bacterial subpopulations with innate resistance (spon-
taneous mutations, as described in particular for fluoroquino-
lone resistance). In so doing, the MPC can account for the
probability of selection for mutant subpopulations.
At the other end of the spectrum are the events occurring
when drug concentrations drop below the pathogen’s MIC.
Examples of undesirable subinhibitory actions of antimicrobials
include as follows:
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a) Enhanced bacterial adhesion to cell surface of host (e.g.,
stimulation of Staphylococcus spp adhesion by subinhibitory
concentrations of florfenicol; Blickwede et al., 2004).
b) Increase in the colony factor expression by (e.g., by moxi-
floxacin susceptible and resistant Clostridium difficile; Deneve
et al., 2008).
c) Rearrangement of bacterial genome (e.g., enhanced gene
transfer in Bacteroides by tetracycline; Song et al., 2009).
d) Upregulation of virulence factors.
e) Increase in biofilm formation, for example, as demonstrated,
for example, for Pseudomonas aeruginosa biofilm formation
that can be increased by subinhibitory concentrations of the
aminoglycosides (Hoffman et al., 2005). The fact that subin-
hibitory concentration of antimicrobials favor biofilm forma-
tion has been demonstrated for almost all veterinary-relevant
bacterial species.
Conversely, subinhibitory concentrations may also have a
positive clinical effect. For example, in addition to the previ-
ously mentioned case of subinhibitory concentrations of clinda-
mycin reducing b-hemolysin expression in cultures of S. aureus
(Marsik & Parisi, 1973), the biofilm and exopolysaccharide for-
mation of Salmonella. enterica serovar Typhimurium can be
inhibited by subinhibitory concentrations of gentamicin or cip-
rofloxacin (Majtan et al., 2008).
Additional references of that may be of interest include Rasi-
gade et al., 2011; Davies et al., 2006; Christensen et al., 2011;
and Reeks et al.,2005.
Part 3: Emergence, transmission, and persistence of antimicrobial
resistance
Mechanisms of resistance and resistance transfer. Numerous
mechanisms for antimicrobial resistance have been identified,
and the impact of these mechanisms appears to be both drug-
and pathogen-specific (Table 2). Examples include efflux
transporters, altered protein targets, genetic mutations, and
enzymatic degradation/modification of the drug that are
mediated by genetic mutations or by acquired resistance genes.
When reflecting on the issue of One World–One Health and
the threat of antimicrobial resistance or resistance transfer, it
was concluded that antimicrobial resistance is a global ecologi-
cal problem impacting the microbiome through such factors as
follows:
a) Use by the human patient: impact on commensal flora,
transfer of resistant human pathogens, and the potential for
transfer of resistance genes:
i) From interpersonal contact
ii) Through the environment (e.g., hospital and community)
iii) Through the environment (e.g., sewage and transfer by
insects and rats)
iv) Transfer of resistant bacterial strains to and from com-
panion animals, and vice versa
b) Use on the farm: impact on commensal flora, zoonotic
pathogens, and the potential for transfer of resistance genes:
i) Through the food chain
ii) Through the environment
Discussions occurring during the AAVM included such issues
as the potential impact of drug use on commensal flora (Figs 1
& 2), the prevalence of the oral route of administration for col-
lective medication, and potential mechanisms through which
even systemically available drug can re-appear in the gastroin-
testinal tract. Complicating potential transmission between
hosts is the long survival time of many pathogens on dry inan-
imate objects (Matlow & Morris, 2009). For example, the
durations of survival for MRSA, VRE, and C. difficile spores
are, respectively, 7 days to 7 months, 5 days to 4 months, and
5 months.
Table 2. Recognized resistant pathogens of human and veterinary health concern
Acronym Definition General information Bacterial pathogens Significance
ESBL Extended spectrum b-lactamase Resistance to 3rd generation
cephalosporins (cefotaxime
resistance)
Escherichia coli, Klebsiella spp.,
and other Enterobacteriaceae
Resistance to most
cephalosporins*
MRSA Methicillin-resistant
Staphylococcus aureus
Resistance to oxacillin S. aureus Resistance to most b-lactams†
PCR – mecA
Chromogenic agar
Cefoxitin resistance
VRE Vancomycin resistant
Enterococcus
Vancomycin screen plate Enterococcus spp. Resistance to vancomycin
PCR-vancomycin resistance
genes
Chromogenic agar
VISA Vancomycin intermediate
resistant S. aureus
Reduced susceptibility to
vancomycin
S. aureus Reduced susceptibility to
vancomycin
VRSA Vancomycin resistant S. aureus Resistance to vancomycin S. aureus Resistance to vancomycin
*Cefotaxime, cefpodoxime, ceftriaxone, and ceftazidime.
†Penicillins, cephalosporins, carbapenems, and monobactams.
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Gut flora resistance: the impact of dosage regime. The potential
impact of metaphylaxis on gut-level resistance was studied in a
rat Klebsiella pneumoniae lung infection model. Marbofloxacin
was administered via subcutaneous injection at either 4 or
24 h after bacterial introduction into the lungs. Total daily
doses were administered as a single injection or as a
fractionated (49/day) dosage regime of 16 or 64 mg/kg.
Regardless of dosage regime, there was little to no impact on
the susceptibility of gut Enterococcus faecium. In contrast, the
E. coli population was affected by dose, with the number of
isolates decreasing to a greater extent with the fractionated as
compared to the single dose groups, and after 7 days of
marbofloxacin treatment, a resistant E. coli subpopulation was
found in all treatment groups. The largest percentage of rats
harboring resistant intestinal E. coli was observed in the dose
group receiving a single high-dose injection of marbofloxacin
(Kesteman et al., 2010).
Similarly, Looft et al. (2012) observed collateral effects of
feeding subtherapeutic doses of antimicrobials to pigs adminis-
tered medicated feed containing sulfamethazine, chlortetracy-
cline, and penicillin in a highly controlled environment.
Bacterial phylotypes shifted after 14 days of antimicrobial
treatment, with the medicated pigs showing an increase in
E. coli populations as compared to the nonmedicated pigs.
Although antimicrobial resistance genes increased in abun-
dance and diversity in the medicated swine microbiome, these
investigators also noted the high background of bacterial resis-
tance genes in the feces nonmedicated swine.
Defining ‘clinical’ vs. ‘biological’ resistance. The term ‘resistance’
can be interpreted from the perspective of epidemiological
surveys (biological resistance) or from that of clinical break
points. This distinction is illustrated in Fig. 3.
To appreciate the implications of any MIC value, there needs
to be consistency in the methods used for its determination,
and the context within the term ‘resistance’ is being defined.
This point is illustrated by the confusion associated with ‘resis-
tance’ as defined on the basis of epidemiological cutoff values
(ECOFFs) vs. that defined by clinical break points. ECOFFs have
been utilized to separate the naive, susceptible, wild-type bacte-
rial population from bacterial isolates that have developed
reduced susceptibility to a given antimicrobial agent (Kahlme-
ter et al., 2003). The ECOFFs can differ from clinical break
points because the latter depends not only on susceptibility
data but also upon such clinically relevant data as therapeutic
indication, clinical response, dosing schedules, and PK/PD rela-
tionships. Therefore, a pathogen can be clinically susceptible
while not belonging to the corresponding wild population, and
vice versa.
Differences in the parameter being measured, the in vitro
methodologies, and how the ECOFF values are defined have
confounded efforts to track global changes in microbial suscep-
tibility patterns (Silley et al., 2011). This has rendered it extre-
mely difficult to compare resistant rates across surveillance
Fig. 1. Potential mechanisms for drug entry into the environment and
food chain were explored through the various presentations. The reci-
pient of the original dose can be either an animal or human patient.
(From the presentation of P.-L. Toutain).
Biophases & antibioresistance
Gastrointestinal tract
Proximal Distal
Intestinal
secretion
bile
Resistance = lack of efficacy
Resistance =public health issue
Biophase
Target pathogen
Blood
Food chain
Environment
Systemic administration
Quinolones
Macrolides
Tétracyclines
Betalactams
Gut flora
•Zoonotic (salmonella, campylobacter 
•commensal  ( enterococcus)
AB: oral route
Fig. 2. Mechanisms for drug exposure in the human and animal intestine following an oral antimicrobial administration of a poorly bioavailable
compound (left) or following administration of a systemically available drug, where the administered compound reenters the gastrointestinal tract
through various potential excretory mechanisms (right) (From the presentation of P.-L. Toutain).
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schemes. Moreover, there is a trend for ‘resistance’ in foodborne
pathogens and commensals to be defined by the ECOFF values
rather than by the long-established clinical break points.
Even if ECOFFs are consistently used, difference can occur
with respect to data interpretation. For example, Sweden has
traditionally not accepted the ECOFF used by European Food
Safety Authority (EFSA) for ciprofloxacin and E. coli
(>0.03 lg/mL) because it cuts through the wild-type MIC,
causing an erroneously high frequency of E. coli classified as
resistant (Anon 8). The Netherlands and Norway have elected
to set the E. coli ECOFF for ciprofloxacin at >0.06 lg/mL. Only
recently has EUCAST (http://mic.eucast.org/Eucast2/) revised
its E. coli ECOFF values for ciprofloxacin from >0.03 to
>0.06 lg/mL. These changes have been adopted by EFSA
(Anon 1).
To insure consistency both between past and future data
assessments and across antimicrobial resistance monitoring
programs, it is necessary to establish a mechanism for global
harmonization of methods for defining the wild-type distribu-
tion. Ultimately, owing to the numerous methodological and
reporting differences that exist between monitoring and surveil-
lance organizations, at present, it is not possible to relate
resistance levels as defined by EUCAST to those defined by The
European Centre for Disease Prevention and Control (EARS-Net;
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/about_
EARS-Net/Pages/about_network.aspx or NARMS. Given the
urgency of this issue, it is important to insure that epidemio-
logical survey data are based upon comparability of sampling
strategies and on methods of MIC determination.
Part 4: Resistance transfer between animals and humans: a focus
on zoonotic pathogens
Antimicrobial Agents in Veterinary Medicine workshop discus-
sions included a summary of the ongoing programmatic
research efforts aimed at better understanding the role of
human medicine vs. veterinary drug use in promoting resis-
tance transfer in zoonotic pathogens.
Campylobacter jejuni. Campylobacter infections are responsible
for 400–500 million cases of diarrhea each year worldwide.
The mortality rate associated with symptomatic Campylobacter
species infection has been estimated at 24 deaths per 10 000
culture confirmed cases, or 200 deaths per year in the USA
(Ruiz-Palacios, 2007). The pathogen is commonly present in
food-producing animals, especially in slaughter-age broiler
chickens, and can be transmitted to humans via contaminated
poultry, water, or milk.
Campylobacter species infection in human patients is gener-
ally associated with mild illness. These diarrheas are frequently
self-curing, and in the vast majority of incidents of acute diar-
rhea in adults, antimicrobials are of no benefit. Most strains of
C. jejuni and Campylobacter coli are susceptible to erythromycin,
azithromycin, gentamicin, tetracycline, and chloramphenicol.
In those cases where antimicrobials are prescribed, the treat-
ment of choice is generally a macrolide such as erythromycin
or azithromycin (Ruiz-Palacios, 2007).
Antimicrobial resistance in Camplylobacter is mediated by
multiple mechanisms depending upon the drug class. These
Fig. 3. Comparison of the underlying answers addressed by clinical vs. epidemiological descriptions of resistance, differences in the underlying
descriptive methods, and the differences in their respective interpretations.
© Published (2014). This article is a U.S. Government work and is in the public domain in the USA.
e8 M. Martinez et al.
include antimicrobial inactivation, target mutation, efflux-medi-
ated extrusion, and reduced uptake of the drug. When compar-
ing across antimicrobial drug classes (tetracyclines, macrolides,
and fluoroquinolones), there is a higher number of resistant
Campylobacter isolates in poultry raised in conventional as com-
pared to organic farms (Luangtongkum et al., 2006) and
increasing prevalence of fluoroquinolone resistance worldwide
(Blaser & Engberg, 2008). Macrolide-resistant Campylobacter is
less prevalent than fluoroquinolone-resistant Campylobacter,
despite the fact that macrolides are more widely used than fluor-
oquinolones in animal production (Lin et al., 2007). This is
likely attributable to the absence of any fitness (survivability)
cost associated with fluoroquinolone resistance. Therefore, fluor-
oquinolone resistance persists even after the selection pressure
is removed (Luo et al., 2005). Thus, the use of fluoroquinolones
in poultry has long-term public health consequences.
ESBL-producing E. coli. Even with ‘prudent use’, there is the
threat of selecting for ESBL-producing microbial strains through
the use of b-lactam antibiotics (especially cephalosporins of the
3rd and 4th generations) and for an increase in the numbers of
multiresistant strains through the use of fluoroquinolones
(particularly in large poultry holdings). Of great concern is the
apparent increase in the number of ESBL E. coli and Salmonella
spp. in the absence of prior exposure to the cephalosporins,
suggesting potential coselection and coresistance.
Based upon recent work, it appears that the largest transmis-
sion pathway for ESBL E. coli is from humans to wildlife and the
environment. Guenther et al. (2010a,b) observed that 16% of
urban rats were carriers of ESBL-producing E. coli and that 33%
of the rats obtained from inside the sewage system located in
close proximity to a university hospital carried ESBL-producing
E. coli. Multilocus sequencing confirmed that the tested rats car-
ried extra-intestinal pathogenic E. coli (ExPEC)-like strains that
typically belonged to a highly virulent lineage isolated primarily
in humans and birds. This finding suggests that the urban rats
may have an important role in the transmission of multiresis-
tant and virulent E. coli strains (Guenther et al., 2012).
Resistant strains of E. coli were also observed in European wild
birds (Guenther et al., 2010b). Accordingly, wild birds might
likewise constitute a potential hazard to human and animal
health by transmitting multiresistant strains to waterways and
other environmental sources via their fecal deposits.
There is also some transmission between humans and com-
panion animal species and from livestock animals to humans
via the consumption of raw meat, milk, and contaminated
vegetables (Ewers et al., 2012). In this regard, the percentages
of animals carrying ESBL-positive E. coli strains included 4% of
the dogs, 3.2% of the cats, 5.1% of the horses, and 3.3% of the
cattle (Ewers et al., 2010). Corresponding human data can be
obtained from the European interactive database (Anon 9).
Transmission pathways of ESBL and AmpC-producing E. coli
are described in Fig. 4.
CTX-M associated ESBLs, enzymes named for their greater
activity against cefotaxime than other oxyimino-b-lactam sub-
strates, are the most widespread type of ESBL E. coli. Strains
relevant to human health are also being isolated with increas-
ing frequency from companion animals, and there is global
occurrence of ESBL carrying bacteria in poultry, cattle, and
pigs. Nevertheless, the high similarity of major ESBL types in
humans, regardless of their geographical origin, points toward
person-to-person transmission as the most important route of
resistance distribution rather than a transmission between
animals and humans (Ewers et al., 2012).
Salmonella spp. Salmonella is an important contributor to
bacterial foodborne infections, particularly in children (CDC,
2013). PCR screening of resistant isolates from food animals
Edible materials
Raw meat, milk
Contaminated fruits 
and vegetables
Wildlife
Environmental 
pollution
Consumption of 
raw meat
Companion animals
Direct contact with 
infected humans
Household exposure
Environment
Soil
Water
Manure/Sewage
Human
Hospital
Community
International travel
Fig. 4. Transmission pathways of extended
spectrum b-lactamase and AmpC-producing
Escherichia coli (based upon Ewers et al.,
2012).
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identified these as serovars that are more often associated with
invasive human infections than are most other serovars. These
include typhimurium (relative proportion to all potential
serotypes: 12% in humans, 3% in chickens, and 3.5% in
turkeys), Heidelberg (3.5% in humans, 14.2% in chickens, and
2.4% in turkeys), and Newport (9.3% in humans, 0.8% in
chickens, and 1.4% in turkeys; Fig. 5).
Antimicrobial resistance in zoonotic Salmonella strains is of
public health concern, as genes are readily transferred from
donor to recipient bacteria via plasmids (Kaldhone et al.,
2008). Importantly, these plasmids frequently contain multiple
resistance genes, with some of the transmissible genes
appearing to facilitate Salmonella invasion and persistence in
macrophages. Plasmids may also contain iron acquisition ope-
rons that can enhance extra-intestinal survival and increase
bacterial virulence in poultry. For example, the VirB/D4 T4SS
plasmids appear to increase the ability to invade and persist in
macrophages. The hope is that through ongoing research, it
may be possible to define factors that drive the dissemination
of plasmids in enteric organisms and, in turn, identify strate-
gies to combat their spread.
A note of interest is that while there has been much debate
about the contribution of veterinary antimicrobial drug use to
the overall resistance development in human pathogens, data
suggest that clinical fluoroquinolone resistance in E. coli and
nontyphoidal Salmonella is generally not observed (de Jong
et al., 2012).
Part 5: Premarketing approval and microbiological acceptable daily
intake
Numerous scientific articles have been recently published on
the importance of the relationship between gut flora and
human health (e.g., Possemiers et al., 2009; Human Microbi-
ome Project Consortium, 2012; Petrof et al., 2012). Because
the human GI tract consists of complex microbial communities,
the issue of altered human gut flora via the ingestion of anti-
microbial residues in food is of potential concern.
It is well recognized that the therapeutic ingestion of antimi-
crobials can alter the ecology of the human intestinal flora
(Jernberg et al., 2010). Disruption of the normal colonization
barrier is a concern when the human is exposed to the much
higher concentrations associated with human therapeutic uses.
This may include disruption of the colonization barrier or an
increase in the population(s) of resistant bacteria (VICH GL-36)
(Anon 6).
With respect to human food safety, microbiological health
concerns are raised when consumption of trace levels of anti-
microbial residues in foods disrupts the human gut colonization
barrier or when it leads to an increase in the population(s) of
resistant bacteria. However, the question is whether the
amount of drug ingested in food can reach the colon (either by
being secreted in the bile, through the intestinal mucosa or
reach the colon as free, unabsorbed drug) and remain biologi-
cally active. Concerns associated with effects of antimicrobial
drug residues on human intestinal flora are founded on the
assumptions:
a) Regardless of route of administration, antimicrobials can
reach the colon due to incomplete absorption or by recircu-
lation via the bile of secretion across the intestinal mucosa.
b) By virtue of their inherent antimicrobial activity, these free
(active) drug concentrations are likely to inhibit at least
part of the rich microbial flora of the gastrointestinal tract.
The acceptable daily intake (ADI) is a measure of the amount
of a specific substance (a residue of a veterinary drug, food addi-
tive, or pesticide) in food or drinking water that can be ingested
(orally) on a daily basis over a human’s lifetime without incur-
ring an appreciable health risk. When evaluating allowable
antimicrobial residues in food, there are two types of ADIs to be
considered: the toxicological ADI, which is based upon labora-
tory animal toxicology data and an estimated no observed
adverse effect level (NOAEL), and the microbiological ADI
(ADIm), which is based upon an assessment of drug effects on
the human gut microflora. The lower of these two values is
used to determine the maximum residue limit (MRL) in Europe
and Canada or the tolerance in the USA. The tolerance and
MRL provide the basis for establishing a withdrawal period (the
time duration between the last drug intake by the animal and
the allowable date for animal slaughter for human food con-
sumption). Additional information on this evaluation procedure
is provided in the VICH Guideline #36 (Anon 9). The European
public MRL assessment reports are available from the EMA
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/medi-
cines/landing/vet_mrl_search.jsp&murl=menus/medicines/med-
icines.jsp&mid=WC0b01ac058008d7ad). In addition, the Joint
FAO/WHO Expert Committee on Food Additives (JECFA) has
public evaluation reports of the effects of the veterinary drug
residues on the human intestinal microbiota http://www.who.
int/foodsafety/chem/jecfa/publications/en/index.html.
Although the original VICH Guideline 36 ADIm Expert
Working Group readily achieved consensus on concerns per-
taining to barrier disruption, the discussion at the AAVM were
indicative of an ongoing scientific debate regarding the impact
of antimicrobial residues on human gut flora (at the concentra-
tion range presented by ingestion of animal-derived food) as a
public health concern. In part, these uncertainties are a func-
tion of the normal daily fluctuations in bacterial populations
within a healthy human intestine.
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Fig. 5. Relative proportion of top serotypes in humans and poultry.
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a) Jeffery et al. (2012) reviewed studies demonstrating that the
human gut microbiota is dynamic and is subject to lifestyle-
induced fluctuations. It is stated that habitual dietary intake
is a major driver of microbiota composition and function.
These effects of diet transcend even mammalian species
boundaries; and therefore, the diet of an individual needs to
be considered before attempting to categorize the gut micro-
biota of that individual.
b) Wu et al. (2011) showed that in ten subjects aged
2–50 years old, two enterotypes were associated with diet:
long-term diets enriched for protein and animal fat were
associated with the Bacteroides enterotype, whereas diets
enriched for carbohydrate were associated with the Prevotel-
la enterotype. Controlled feeding over the duration of
10 days can lead to arrangement of the microbiota compo-
sition but did not lead to any change in enterotypes.
Thus, efforts to characterize the clinically relevant impact of
low level drug residues are extremely complex and should be
evaluated from the perspective of natural variations that occur
in humans.
When determining the ADIm, the calculated MIC is based on
the susceptibility of those genera for which the antimicrobial is
active. Discussions focused on critical uncertainties associated
with these tests. Firstly, ADIm studies will not be able to suffi-
ciently address all of the variables that are inherent in the
human gut flora, human populations, candidate molecule
behavior, and other factors. Secondly, regardless of the tech-
nology or methodology employed, the results of these methods
need to be placed within the context of a public health impact.
Changes detectable by very sensitive and specific methods may
have no consequence. In addition, the test conditions them-
selves are not straightforward (Ahn et al., 2010; Kim et al.,
2011, 2012). A list of critical variables impacting the outcome
from these studies is provided in Table 3 (from C. Cerniglia,
National Center for Toxicological Research [NCTR], FDA).
Many attendees also emphasized that the approach to the
ADIm for colonization barrier effects and resistance develop-
ment are fundamentally different. For the former, it is possible
to conduct simple MIC studies and/or alternative short-term in
vitro approaches. For the latter, complex long-term in vivo or in
vitro population studies are needed.
While the current guideline offers alternative approaches to
addressing the ADIm, many attendees encouraged drug spon-
sor and regulatory authorities to dialog on appropriate study
approaches, emphasizing that ‘one size does not fit all’.
Requests were made regarding the need for consensus on the
group of bacteria that constitute a potential public health con-
cern [particularly when we consider the normal gut flora of
each individual person may not be the same (Jeffery et al.,
2012)]. It was noted that the guideline itself states that ‘Preli-
minary information regarding the prevalence of resistance in
the human intestinal flora, such as daily variation within indi-
viduals and the variation among individuals can be useful in
developing criteria for evaluating resistance emergence. MIC
distributions of sensitive and known resistant organisms of
concern can provide a basis to determine what drug concen-
tration should be used in the selective agar media to enumer-
ate resistant organisms in the fecal samples’ (VICH GL-36).
Based upon studies conducted at the NCTR and the pub-
lished scientific literature, it became clear that the results and
conclusions are highly dependent upon experimental methodol-
ogy. Accordingly, unless we can identify relevant conditions
and validate methods that will be applicable and predictive
across the human population, the interpretation of studies on
the effects of antimicrobial residues on the human intestinal
microbiota is incompletely understood. Furthermore, the
expressed opinion was that antimicrobial drug residues are
inherently low due to the conservative nature of the assign-
ment of ADIs, MRLs, and withdrawal times.
Regarding the end point of disruption of colonization barrier,
the current research gaps identified by experts at the NCTR
include the following:
a) The need to validate and determine the predictive capabili-
ties of in vitro or in vivo test systems to determine impact of
drug residues on human intestinal microbiota and identify-
ing potential adverse human health effects.
b) The need to design research protocols that are relevant and
reproducible to evaluate fecal inactivation due to drug bind-
ing in test systems to address impact of antimicrobial resi-
dues on the human intestinal microbiota.
c) The need to establish databases that describe the variability
of the intestinal microbiota, typically observed among or
within individuals. This information is critical for determin-
Table 3. Overview of the methodological aspects to consider when
interpreting the results in vitro barrier disruption studies
Methods Aspects for consideration
Physicochemical
characterization of fecal
samples
Water and solid content
Fecal viscosity
Short-chain fatty acids
pH
Water-holding capacity
Drug binding/inactivation
assay
Compare microbiological and
analytical chemistry assays
Compare fecal concentrations
Compare incubation time
Compare pellet vs. supernatant
Compare sterilization methods
Evaluate the biotransformation of
the drug
Predict the in vitro inactivation of
the drug by regression analysis
Microbial community analysis
of fecal samples
Characterization of the fecal
microbiota by culture dependent
and culture independent
methods
Selective plate media
Flow cytometry
PCR
Denaturing gradient gel
electrophoresis (DGGE) and
pyrosequencing
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ing the magnitude of change in commensal and resistant
populations (following exposure to antimicrobial drug resi-
dues in food) that may pose a risk to public health.
d) The development of model systems that can statistically
account for the inherent variability within individuals and
normal intestinal microbiota.
e) A clearly defined end point for identifying ‘disruption of
colonization barrier’ of the human intestinal microbiota.
f) A need to define the scope of representative microbiota
considered sufficiently comprehensive when generating a
microbial food safety assessment.
g) A need to identify appropriate microbial growth conditions
that reflect the conditions within the human gut. Recent
research from FDA–NCTR demonstrated that intestinal bac-
teria from normal human subjects are greatly affected by
the selection of growth media. Considering that the nutri-
tional variations in human diets function as different types
of growth media, it is not surprising that intestinal microbi-
ota fluctuate in response to diet.
h) The need to determine whether or not use of currently
available methods for estimating the MIC is appropriate for
evaluating antimicrobial drugs effect on intestinal barrier
functions.
Although definitive evidence is not currently available, the
data and literature (Cerniglia & Kotarski, 1999, 2005) pre-
sented at this workshop resulted in many attendees voicing the
opinion that dietary consumption of microbiologically active
drug residues is unlikely to either be a major factor in the
development of antimicrobial resistant bacteria in the normal
human intestinal flora or a cause of disruption of the normal
human colonization barrier. While these issues are controver-
sial, further consideration of the literature and research is
needed for a full understanding of this complex issue.
Part 6: Maintaining an affordable, safe, and abundant food supply
By 2050, the global needs for food will increase by 70% more
food. According to FAO, and as expanded upon below, 70% of
these needs must come from efficiency-enhancing technologies.
These include as follows:
a) Practices – Doing it better.
b) Products – Using new, innovative tools, and technologies.
c) Genetics – Enhance desired traits in plants and animals.
The means and tools that should or need be used in effi-
ciency-enhancing technologies remain, however, a matter of
controversial debate. We need to ‘call a truce’ to the debate
over the role of technology in the sustainable production of
safe, affordable, and abundant food if we are to protect the
three rights:
a) Ensuring the right of all people around the world to have
access to affordable food.
b) Protecting all consumers’ rights to spend their food budget
on the widest variety of food choices.
c) Creating a sustainable global food production system that
does not compromise the health of humans and animals or
the integrity of the environment.
The challenge of overcoming world hunger is complex and
multifaceted. Allowing the entire food chain access to safe, effi-
ciency-enhancing technologies is an essential component of a
comprehensive solution to this challenge – both locally and
globally. In addition, protecting the right to choose these tech-
nologies can make the dream of safe, affordable, and abundant
food a reality worldwide.
As the issue of antimicrobial resistance in veterinary medi-
cine is debated, the need to insure food availability, changes in
husbandry practices necessary to meet a growing food demand,
and the corresponding importance of therapeutics to insure
animal health and welfare needs to be considered because ani-
mals are no longer simply considered to be ‘walking food’. Ulti-
mately, the availability of appropriate interventions for
maintaining animal health and for maximizing their productiv-
ity will be a fundamental component in our ability to meet the
global nutritional requirements critical for insuring public
health.
Part 7: Facing future challenges
Concerns associated with the relationship between traditional
antimicrobials and the propagation of resistant pathogens have
led to efforts to identify alternative therapeutic targets and
approaches. Much effort is currently focusing on the inhibition
of virulence factors. Potential antivirulence targets have been
reviewed elsewhere (Cegelski et al., 2008; Escaich, 2010).
Although such a therapeutic paradigm shift may have its mer-
its, important limitations need to be considered. For example, if
the drug does not influence bacterial viability, cure of infection
will primarily rely upon the ability of the host immune system
to clear the infection. In turn, the use of such agents as a
stand-alone therapy seems to be limited to mild infections or
disease prophylaxis.
Although the majority of this workshop focused on drug use
in food-producing animals, issues and concerns impacting ther-
apeutics in companion animal species were also discussed.
When dealing with companion animal species, medication
challenges include the absence of culture and antimicrobial
susceptibility data (with poor owner compliance for follow-up
cultures when they are prescribed), the lack of approved anti-
microbials to cover the many unmet needs, and a paucity of
information regarding the effectiveness of extra-label indica-
tions (e.g., approved drugs are usually targeted for skin and
soft tissue infections). The importance of having animal spe-
cies-specific drug approvals is critical for a variety of reasons
including the following:
a) The need to address the metabolic idiosyncrasies of each ani-
mal species and the potential species-specific safety concerns.
b) Physiological differences may lead to differences both in
drug PK and disease response.
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c) There is a need for body weight-appropriate animal-friendly
dosage forms to encourage owner compliance with the pre-
scribed dosage regime.
In addition to the need for drugs to treat the range of infec-
tious diseases encountered in pets, recent publications suggest
that drug resistance is an increasing challenge in companion
animal medicine (JAVMA, 230, News Feb 1, 2007; van Duijk-
eren et al., 2004a,b; Jones et al., 2007; Bemis et al., 2009;
Papich, 2012).
As we enter into a global regulatory environment, there is a
need for harmonization and international collaboration. In
turn, this raises questions such as:
a) How can the regulatory bodies in different countries share
data on products?
b) Can we agree upon a single set of studies to support appli-
cations submitted to the different competent authorities (as
e.g., EMA, FDA, and others)?
c) How can we promote greater international consistency in
product labeling guiding the correct and prudent use of
antimicrobials?
d) Can we agree upon criteria and test methods (including
sampling protocols) for monitoring regional and global
shifts in susceptibility trends over time? The need for such
monitoring programs will likely increase as we strive
toward improving our dosing strategies.
e) In addition to pharmaceutical intervention, there is a need to
examine potential methods for modifying husbandry prac-
tices (genetics, feeding, housing, biosecurity etc.) in an effort
to reduce antimicrobial use. How we can stimulate the
implementation of such advanced practices at a global level?
Finally, some attendees expressed a desire for regulatory
authorities to reinstate flexible labeling-type concepts that will
enable veterinarians to have the freedom to adjust doses when
medically appropriate. In so doing, the practitioner can better
select the dose and regimen that addresses the specific clinical
situation.
CLOSING REMARKS
Although the availability of antimicrobial therapies for animals
remains essential (both for pets and for farm animals), the
availability of these agents may be threatened by exaggerated
perceptions of the public health impact of veterinary drug use.
At least in part, this concern reflects a reliance on estimates of
antibiotics tonnages used in human and veterinary medicine,
even though these two estimates are not directly comparable.
The veterinary community needs to be assured of the contin-
ued availability of effective treatments and the ability to pre-
scribe the moieties necessary to treat their patients. To support
this goal, the animal health community is actively involved in
the development of state-of-the-art tools and approaches to
assure that drugs are used in a manner consistent with public
and animal health. Efforts and needs to achieve the goals
include as follows:
a) Advanced genetic test (multilocus sequencing) methods to
track the transfer of resistance elements and to understand
the transmission of resistant microbial strains.
b) PK/PD approaches to target the right dose of the right drug
and for the shortest duration possible for achieving the
desired therapeutic effect.
c) Utilization of innovative drug delivery technologies and
identification of novel bacterial targets.
d) Better use of clinical laboratory susceptibility testing to
insure appropriate drug selection.
e) Antimicrobial resistance monitoring and a global harmoni-
zation of susceptibility test methods allowing consistent
definitions of ‘resistance’.
f) Separation of investigations aiming to document biological
vs. clinical resistance.
g) Availability of approved drug products with appropriate dos-
age regimes insure the application of the right dose for the
right duration.
h) Implementation of strategies for insuring that all antimicro-
bial products meet the same quality control standards that
are imposed during the approval of new animal drug appli-
cations.
i) Availability of user-friendly applications (animal acceptabil-
ity and convenient dosage regimes).
j) Stimulation of basic (veterinary schools) and continuing edu-
cation and continuing critical review of prescribing practices.
k) Implementation of responsible use guidelines for antimicro-
bials that are practical and are translated into animal
workers language.
Living in the current global environment, what happens in
one part of the world will eventually impact all others. Accord-
ingly, international guidelines for prudent use are being estab-
lished. The combination of prudent/judicious use practices and
surveillance/residue and microbial monitoring systems will
ensure that we can meet the needs associated with animal
health while avoiding a negative impact on human health
care.
Without the necessary therapeutic options, we will be unable
to adequately control animal diseases. As we allow our food
and companion animals to serve as reservoirs for inadequately
treated infections, there will be an ever-growing potential for
the spread of zoonotic diseases. Considering also the demands
for animal of an ever-growing human population, the animal
health community is striving to insure appropriate drug in
light of the common goal of ‘One World Health’.
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